Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 (Reuters) - A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc. The verdict had been the largest ever in a U.S. patent case but U.S. District Judge Leonard Stark in Wilmington, Delaware, on Friday ruled Merck’s patent was invalid. He said it did not meet a requirement that it disc

U.S.: Kids With Hepatitis C Get New Drugs And Coverage May Prove Easier Than For Adults

With the approval this month of two drugs to treat hepatitis C in children, these often overlooked victims of the opioid epidemic have a better chance at a cure. Kids may have an easier time than adults getting treatment approved, some experts say. Medicaid programs and private insurers have often balked at paying for the pricey drugs for adults, but stricter Medicaid guidelines for kids may make coverage more routine. The two drugs approved for pediat

Gilead gets patent for Hepatitis C drug Sovaldi

The decision is a major blow to the access to drug movement, says MSF In direct contradiction to its earlier order, the Controller General of Patents, Designs and Trademark granted American pharmaceutical company Gilead Sciences the patent for the blockbuster Hepatitis C drug Sofosbuvir (brand name Sovaldi) in India. An application for the same patent was first rejected in January 2015 as lacking inventiveness and novelty. On Monday, however, the pa...

Abbotsford man cured of hepatitis C by new, expensive treatment

An Abbotsford man wants the provincial government to fund more people to receive the medication that cured him of chronic hepatitis C, a viral liver disease. Chris Robinson, 56, said it looked like he was on his way to receiving a long-awaited liver transplant to save his life last year when doctors told him, “Transplant? Remove it from your vocabulary.” At the time, Robinson had been in the midst of a six-month course of a relatively new treatment that


PATIENT GROUP SUBMISSIONS to BC PharmaCare, CADTH, & PMPRB Whenever we are asked to contribute a patient group submission about a hepatitis-C or hepatitis-B related product, we do so. We contribute as a patient group to reviews by both BC PharmaCare (to determine whether BC PharmaCare patients will be reimbursed for the drugs) and CADTH (federal level – to determine whether the drugs will be available in Canada). Occasionally we also submit patien

Current Treatments

Current HCV Treatments in BC as of March 2019 IMPORTANT: As of March 13, 2018,  anyone in B.C. living with this now-curable virus will have a choice of several treatment options – all of which are fully funded under BC PharmaCare, and all restrictions based on disease level have been removed. There are many drug combinations available for treating hepatitis C in Canada which are also covered by BC Pharmacare.  Older combinations involved the use of i

Hepatitis C patient: ‘…Price gouging was a crime, or isn’t it?’

GRAND HAVEN, Mich. (WZZM) -- Drugs that are almost 100 percent effective in curing Hepatitis C are so expensive, many patients are unable to get them. Some private health insurance companies refuse to cover the drugs, and Medicaid has resisted paying for them. Officials contend that to provide the drugs to all patients that need them could bankrupt the health care system.The cost for treatments begin at just under $100,000, but they can go as high as twice

Patient Input Requested for Merck Interferon-Free Combo

HepCBC is seeking individual patient input for our submission to the federal government for an INTERFERON-FREE, ONE PILL/DAY drug combo, shown to be effective for genotypes 1, 3, 4, and 6, Merck Pharmaceutical's elbasvir + grazoprevir (± ribavirin). The treatment's success (96% - 100% SVR12) has been confirmed in trials including people considered 'hard to treat' including those who had failed previous treatment (including simeprevir, boceprevir, and telap

Hepatitis C Elimination Experiment Launched in Georgia

Eastern Europe's Republic of Georgia, with a population of 5 million - of which 7% has hepatitis C - has approximately 350,000 HCV+ people, similar to the number with the disease in Canada. The country, with minimal resources for fighting such an epidemic, has teamed up with the maker of SOVALDI and HARVONI to attempt to demonstrate that, with careful planning and using new hepatitis C drugs, hepatitis C can be eliminated. The company, Gilead, is providing

Updated: HepCBC Patient Group Submissions to CADTH and BC Pharmacare

To view all submissions (2011 to present) HepCBC has made to either CADTH (to determine if drug should be allowed for sale in Canada for a specific purpose) and BC Pharmacare (to determine if drug should be covered/purchase reimbursed by Pharmacare) please see this updated link: